Puma Biotechnology (PBYI) Total Liabilities (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Total Liabilities data on file, last reported at $64.3 million in Q1 2026.

• Quarterly Total Liabilities fell 35.12% year-over-year to $64.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.3 million (down 35.12% YoY) and the FY2025 annual result came in at $86.0 million, down 29.08% from the prior year.
• Total Liabilities slipped to $64.3 million in Q1 2026, from $86.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $200.5 million in Q4 2022 to a low of $64.3 million in Q1 2026.
• A 5-year average of $143.8 million and a median of $163.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities retreated 2.2% — and 2025, when it sank 42.36%.
• Tracing PBYI's Total Liabilities over 5 years: stood at $200.5 million in 2022, then decreased by 11.66% to $177.1 million in 2023, then sank by 31.55% to $121.2 million in 2024, then dropped by 29.08% to $86.0 million in 2025, then fell by 25.22% to $64.3 million in 2026.
• The last three Total Liabilities figures came in at $64.3 million (Q1 2026), $86.0 million (Q4 2025), and $87.6 million (Q3 2025), per Business Quant data.